Abstract. Background: Activating mutations in KRAS (including KRAS G12V) are well-described oncogenic drivers in solid tumors. Patients with KRAS driver mutations have a poor prognosis, and most ...

AbstractBackground:. The five-year survival rate for colorectal cancer (CRC) remains at 14% despite improvements in early detection and the development of novel treatments, underscoring the need for ...

Abstract. Background: KRAS mutations are the most frequently encountered driver oncogene, involved in ~25% of all human cancers [1,2]. KRASG12D is the predominant KRAS mutation isoform, detected in ...

A major challenge in treatment of acute myeloid leukemia (AML) is the elimination of leukemia stem and progenitor cells (LSC). LSCs represent therapy-resistant cells that persist after treatment and ...

Our study addresses the urgent need for treatment strategies for TKI-resistant gastrointestinal stromal tumors (GIST). We have identified a non-TKI compound, OPB-171775, that exhibits significant ...

Abstract. The Hippo pathway, a critical cell proliferation regulator, remains an underexplored oncogenic pathway in precision oncology. It is executed through YAP1/TAZ co-activators and the TEAD ...

Abstract. Background: ASC63 is an oral small molecule programmed cell death-ligand 1 (PD-L1) inhibitor. After oral dosing, ASC63 is rapidly absorbed and converted to its pharmacologically active ...

The American Society for Radiation Oncology (ASTRO) issued new guidance on using radiation therapy to treat grade 4 diffuse gliomas, which account for nearly half of malignant brain tumors in adults ...

Abstract. Background: The 3rd-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), like osimertinib, provide marked clinical benefit for EGFR-mutant non-small cell lung ...

In the pooled cohorts, the median biochemical PFS were 26.1 and 15.0 months (P = 0.005), and the median radiographic PFS were 36.0 and 25.0 months (P = 0.003) for PSMA + EV-low and -high groups, ...

The FDA removed the Risk Evaluation and Mitigation Strategies (REMS) requirements for approved BCMA- and CD19-targeting chimeric antigen receptor (CAR) T-cell therapies. The FDA can require a REMS ...

The FDA gave accelerated approval to datopotamab deruxtecan (Datroway; Daiichi Sankyo), a TROP-2 targeting antibody–drug conjugate (ADC), for patients with advanced or metastatic EGFR-mutated ...